The inclusion criteria for the Phase 2a Blarcamesine Alzheimer's disease treatment trial originally allowed the use of donepezil, BUT that was removed during the progression of the trial.
If a participant is taking donepezil (allowed acetylcholinesterase inhibitor) then the medication must be maintained on a stable dose regimen for at least 90 days prior to screening evaluations. Donepezil dose is limited to 20 mg/day (with 10mg/d being the maximal recommended daily dose in Australia).
Market Data 
Markets 
AI
